The enzyme replacement therapy started in late 2000, when researchers from BioMarin, a Novato-based pharmaceutical company, approached Dr. Paul Harmatz at Oakland Children's Hospital about setting ...

According to SNS Insider, The Enzyme Replacement Therapy Market was estimated at USD 11.27 billion in 2024 and is expected to reach USD 21.70 billion by 2032, at a CAGR of 8.59% during the ...

Of the more than 50 known lysosomal storage diseases (LSDs)-rare inherited metabolic disorders-only seven can be treated with approved enzyme-replacement therapies. Lysosomal acid lipase ...

Enzyme-replacement therapy may slow disease progression and improve motor function in children with Pompe disease, according to a poster from the 2024 Muscular Dystrophy Association Clinical ...

Purpose: Enzyme replacement therapy (ERT) is a promising therapeutic intervention for lysosomal storage diseases. Posttranslationally engineered human β-glucocerebrosidase (Ceredase®/Cerezyme ...

FDA Approves Revcovi™, a New Enzyme Replacement Therapy Developed by Leadiant Biosciences, for the Treatment of ADA-SCID in Pediatric and Adult Patients ...